Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.

Saved in:
Bibliographic Details
Title: Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
Authors: Rha SY; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Songdang Institute for Cancer Research, Seoul, Republic of Korea., Castanon E; Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain., Gill S; Medical Oncology Department, Alfred Hospital, Melbourne, Victoria, Australia., Senellart H; Integrated Center for Oncology, Centre René Gauducheau, Saint Herblain, France., Lopez J; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK., Márquez-Rodas I; Hospital General Universitario Gregorio Marañon and Universidad Complutense, Madrid, Spain., Victoria I; Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain., Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Lwin Z; Royal Brisbane and Women's Hospital, University of Queensland, Herston, Queensland, Australia., Burger MC; Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany., Simonelli M; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy., Cassier PA; Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France., Hendifar AE; Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Dutcus C; Eisai Inc., Nutley, New Jersey, USA., Okpara CE; Eisai Ltd., Hatfield, UK., Ghori R; Merck & Co., Inc., Rahway, USA., Jin F; Merck & Co., Inc., Rahway, USA., Groisberg R; Merck & Co., Inc., Rahway, USA., Villanueva L; Department of Oncology, Instituto Oncologico Fundacion Arturo Lopez Perez, Hospital Clinico Universidad de Chile, Santiago, Chile.
Source: Cancer [Cancer] 2025 Aug 15; Vol. 131 (16), pp. e70015.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0142
DOI:10.1002/cncr.70015